CVS Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 1.68% compared to CVS Health's net margin of 23.56%. CVS Health's return on equity of 6.12% beat Gilead Sciences's return on equity of 2.5%.

CVS Health has a consensus price target of $73.26, signalling upside risk potential of 5.39%. On the other hand Gilead Sciences has an analysts' consensus of $112.46 which suggests that it could grow by 8.52%. Given that Gilead Sciences has higher upside potential than CVS Health, analysts believe Gilead Sciences is more attractive than CVS Health.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.622% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.322, suggesting its less volatile than the S&P 500 by 67.831%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.83%. Gilead Sciences offers a yield of 2.99% to investors and pays a quarterly dividend of $0.79 per share. CVS Health pays 73.1% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Gilead Sciences's is not.

CVS Health quarterly revenues are $97.7B, which are larger than Gilead Sciences quarterly revenues of $7.6B. CVS Health's net income of $1.6B is lower than Gilead Sciences's net income of $1.8B. Notably, CVS Health's price-to-earnings ratio is 18.99x while Gilead Sciences's PE ratio is 280.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.24x versus 4.53x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Humana has a net margin of 1.68% compared to CVS Health's net margin of -2.37%. CVS Health's return on equity of 6.12% beat Humana's return on equity of 7.25%.

CVS Health has a consensus price target of $73.26, signalling upside risk potential of 5.39%. On the other hand Humana has an analysts' consensus of $305.42 which suggests that it could grow by 3.52%. Given that CVS Health has higher upside potential than Humana, analysts believe CVS Health is more attractive than Humana.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.622% less volatile than S&P 500. In comparison Humana has a beta of 0.624, suggesting its less volatile than the S&P 500 by 37.637%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.83%. Humana offers a yield of 1.2% to investors and pays a quarterly dividend of $0.89 per share. CVS Health pays 73.1% of its earnings as a dividend. Humana pays out 35.71% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $97.7B, which are larger than Humana quarterly revenues of $29.2B. CVS Health's net income of $1.6B is higher than Humana's net income of -$693M. Notably, CVS Health's price-to-earnings ratio is 18.99x while Humana's PE ratio is 29.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.24x versus 0.30x for Humana. Usually stocks with elevated PS ratios are considered overvalued.

Walgreens Boots Alliance has a net margin of 1.68% compared to CVS Health's net margin of -7.39%. CVS Health's return on equity of 6.12% beat Walgreens Boots Alliance's return on equity of -46.98%.

CVS Health has a consensus price target of $73.26, signalling upside risk potential of 5.39%. On the other hand Walgreens Boots Alliance has an analysts' consensus of $12.29 which suggests that it could grow by 14.03%. Given that Walgreens Boots Alliance has higher upside potential than CVS Health, analysts believe Walgreens Boots Alliance is more attractive than CVS Health.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.622% less volatile than S&P 500. In comparison Walgreens Boots Alliance has a beta of 0.671, suggesting its less volatile than the S&P 500 by 32.877%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.83%. Walgreens Boots Alliance offers a yield of 9.28% to investors and pays a quarterly dividend of $0.25 per share. CVS Health pays 73.1% of its earnings as a dividend. Walgreens Boots Alliance pays out -14.59% of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $97.7B, which are larger than Walgreens Boots Alliance quarterly revenues of $38.6B. CVS Health's net income of $1.6B is higher than Walgreens Boots Alliance's net income of -$2.9B. Notably, CVS Health's price-to-earnings ratio is 18.99x while Walgreens Boots Alliance's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.24x versus 0.06x for Walgreens Boots Alliance. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx has a net margin of 1.68% compared to CVS Health's net margin of -55.94%. CVS Health's return on equity of 6.12% beat SCWorx's return on equity of -80.46%.

CVS Health has a consensus price target of $73.26, signalling upside risk potential of 5.39%. On the other hand SCWorx has an analysts' consensus of -- which suggests that it could fall by --. Given that CVS Health has higher upside potential than SCWorx, analysts believe CVS Health is more attractive than SCWorx.

CVS Health has a beta of 0.574, which suggesting that the stock is 42.622% less volatile than S&P 500. In comparison SCWorx has a beta of 3.403, suggesting its more volatile than the S&P 500 by 240.336%.

CVS Health has a quarterly dividend of $0.67 per share corresponding to a yield of 3.83%. SCWorx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health pays 73.1% of its earnings as a dividend. SCWorx pays out -- of its earnings as a dividend. CVS Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health quarterly revenues are $97.7B, which are larger than SCWorx quarterly revenues of $759.7K. CVS Health's net income of $1.6B is higher than SCWorx's net income of -$425K. Notably, CVS Health's price-to-earnings ratio is 18.99x while SCWorx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health is 0.24x versus 0.37x for SCWorx. Usually stocks with elevated PS ratios are considered overvalued.